×
About 81,153 results

ALLMedicine™ Anemia Center

Research & Reviews  22,434 results

FDA Approval Summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastati...
https://doi.org/10.1158/1078-0432.CCR-22-2875
Clinical Cancer Research : an Official Journal of the Ame... Fallah J, Agrawal S et. al.

Dec 6th, 2022 - On March 23, 2022, the United States Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-posi...

Surgical treatment of proximal femoral fractures in centenarians: prevalence and outcom...
https://doi.org/10.1007/s00068-022-02184-7
European Journal of Trauma and Emergency Surgery : Offici... Langenhan R, Müller F et. al.

Dec 6th, 2022 - This study aimed to estimate the survival rate after proximal femoral fracture insult and identify the subgroup of centenarians with a high risk. Records of patients (≥ 65 years) who underwent surgery for PFF between 2006 and 2020 were retrieved f...

The efficacy and safety of low-dose temozolomide maintenance therapy in elderly patient...
https://doi.org/10.21037/apm-22-1255
Annals of Palliative Medicine; Tao Q, Zhu T et. al.

Dec 6th, 2022 - Radiotherapy combined with temozolomide chemotherapy (STUPP regimen) is the standard treatment regimen for newly diagnosed glioblastoma (GBM). It is considered feasible to prolong the treatment cycle of temozolomide (TMZ), however, the efficacy an...

History and current standard of postnatal management in hemolytic disease of the fetus ...
https://doi.org/10.1007/s00431-022-04724-0
European Journal of Pediatrics; De Winter DP, Hulzebos C et. al.

Dec 6th, 2022 - Since the discovery of the Rh blood group system in 1940, a greater understanding of hemolytic disease of the fetus and newborn (HDFN) was gained. In the years thereafter, researchers and clinicians came to the current understanding that fetal and...

Association between heme oxygenase one and sepsis development in patients with moderate...
https://doi.org/10.1186/s40001-022-00915-5
European Journal of Medical Research; Chen HY, Tzeng IS et. al.

Dec 5th, 2022 - Heme oxygenase one (HO-1) is considered a poor prognostic factor for survival in patients with severe-to-critical coronavirus disease (COVID-19), but the clinical correlation between heme catabolism biomarkers and COVID-19-related sepsis is unknow...

see more →

Guidelines  27 results

AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Exp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740554
Gastroenterology Shah SC, Piazuelo MB et. al.

Aug 30th, 2021 - The purpose of this Clinical Practice Update Expert Review is to provide clinicians with guidance on the diagnosis and management of atrophic gastritis, a common preneoplastic condition of the stomach, with a primary focus on atrophic gastritis du...

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improvin...
https://doi.org/10.1016/j.kint.2021.03.020
Kidney International; Babitt JL, Eisenga MF et. al.

Apr 12th, 2021 - In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis,...

Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia.
https://doi.org/10.1053/j.gastro.2020.08.036
Gastroenterology Ko CW, Siddique SM et. al.

Aug 31st, 2020 - Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Altayar O,|blood,diagnosis,etiology,standards,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagn...

GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool.
https://doi.org/10.1053/j.gastro.2020.08.043
Gastroenterology

Aug 31st, 2020 - GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool.|2020| ,|blood,diagnosis,etiology,standards,methods,standards,standards,diagnostic imaging,metabolism,pathology,standards,blood,complications,diagnosis,pathology,analysis,diag...

AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency ...
https://doi.org/10.1053/j.gastro.2020.06.046
Gastroenterology Ko CW, Siddique SM et. al.

Aug 19th, 2020 - AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia.|2020|Ko CW,Siddique SM,Patel A,Harris A,Sultan S,|blood,diagnosis,epidemiology,etiology,standards,standards,diagnostic imaging,metabolism,pathology,stan...

see more →

Drugs  1,149 results see all →

Clinicaltrials.gov  2,812 results

Pomalidomide for the Treatment of Bleeding in HHT
https://clinicaltrials.gov/ct2/show/NCT03910244

Oct 14th, 2022 - HHT is associated with substantial morbidity, leading to a reduced quality of life, decreased rate of employment and a high incidence of depression. There currently exists no medical therapy recognized as consistently efficacious in HHT. Reports o...

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04933539

Oct 14th, 2022 - Background: Smoldering multiple myeloma (SMM) is a precursor condition to MM defined by the clinical parameters of M-protein >=3.0 g/dL or bone marrow plasma cells >=10%, and absence of end organ disease. Patients with high-risk SMM have a risk of...

Cancer in Inherited Bone Marrow Failure Syndromes
https://clinicaltrials.gov/ct2/show/NCT00027274

Oct 14th, 2022 - Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic ca...

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT04472598

Oct 14th, 2022 - Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low ...

Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
https://clinicaltrials.gov/ct2/show/NCT03988608

Oct 14th, 2022 - This is a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Chinese subjects with refractory or relapsed severe aplastic anemia (SAA). Treatment with eltrombopag will be started at 25 mg/day and increas...

see more →

News  5,756 results

Is Finding and Fixing Iron Deficiency in Heart Failure Beneficial? IRONMAN in Detail
https://www.medscape.com/viewarticle/983652

Nov 30th, 2022 - This transcript has been edited for clarity. Ileana L. Piña, MD, MPH: Hi. I'm Ileana Piña, heart failure transplant cardiologist and quality chief at Thomas Jefferson in Philadelphia. This is my blog from the American Heart Association meeting in ...

Selpercatinib Approval in RET Fusion+ Solid Tumors Expands Tumor-Agnostic Feasibility
https://www.onclive.com/view/selpercatinib-approval-in-ret-fusion-solid-tumors-expands-tumor-agnostic-feasibility

Nov 23rd, 2022 - Recent FDA approvals for the RET kinase inhibitor selpercatinib (Retivmo) in RET fusion–positive non–small cell lung cancer (NSCLC) and for those with solid tumors bolsters efforts to expand the use of tumor-agnostic drugs in early-stage treatment...

Cilta-cel Induces Strong Response in Chinese Patients With Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/cilta-cel-induces-strong-response-in-chinese-patients-with-relapsed-refractory-multiple-myeloma

Nov 21st, 2022 - Ciltacabtagene autoleucel (cilta-cel; Carvykti) produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma (RRMM) treated at 8 sites in China.1 Investigators said the results from the pivotal phase 2 CARTIFAN...

FDA Approves Additional Dosing Schedule for Rylaze in ALL and LBL
https://www.onclive.com/view/fda-approves-additional-intramuscular-dosing-schedule-for-rylaze-in-all-and-lbl

Nov 18th, 2022 - The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday (MWF) intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).1 In June 2021, Rylaze was approved for use a...

Updated Efficacy and Safety of Larotrectinib in Patients with Advanced Tropomyosin Receptor Kinase (TRK) Fusion Positive Thyroid Carcinoma
https://www.onclive.com/view/updated-efficacy-and-safety-of-larotrectinib-in-patients-with-advanced-tropomyosin-receptor-kinase-trk-fusion-positive-thyroid-carcinoma

Nov 18th, 2022 - Background Larotrectinib is a highly selective TRK inhibitor which has shown a 71% overall response rate (ORR) in 28 investigator-evaluable patients with TRK fusion-positive thyroid carcinoma (TC) as of July 2020. We report data on an expanded d...

see more →

Patient Education  283 results see all →